Kyowa Kirin to invests in expanding US biologics manufacturing
Japanese drugmaker Kyowa Kirin (TYO: 4151) yesterday revealed it is establishing a new, state-of-the-art manufacturing facility in Sanford, North Carolina, in the USA.
Kyowa Kirin said it00 will invest up to $530 million in the construction of a 15,951m2 (171,700-square-foot), two-bioreactor facility, scheduled to break ground in the third quarter of 2024. The new facility will accelerate Kyowa Kirin’s development and production of biologic therapies for patients with debilitating diseases that have unmet medical needs.
“I am very excited to announce that Kyowa Kirin decided to construct a new manufacturing plant for biologics drug substance in the United States,” said Toshiyuki Kurata, chief supply Chain officer, and global manufacturing head at Kyowa Kirin.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze